(Source: MARKETWIRE)David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i(R) nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention. Vicor also has filed several patents associated with the development of peptides and proteins derived from "state-dependent" physiologies to advance the treatment of a wide variety of human conditions.

The Australian Deed of Letters Patent (#2003209030) is valid through February 5, 2023 (20 years from the filing date). Vicor's altered state physiology drug development platform is based on the clinical peptides and proteins derived from "state-dependent" physiologies. This platform may be used to advance the treatment of an array of human conditions, including stroke ischemia, cardiac ischemia, kidney failure, hypertension, obesity, cancer, and organ transplant/preservation, by reducing the cost, time, and risk associated with bringing related pharmaceuticals to market.

"This is the third international patent we've received for our drug development platform in its entirety and we're hopeful that we'll receive notice from the U.S. patent office no later than the first quarter of 2010," stated Mr. Fater. "We believe our drug development platform has significant advantages over the drug development process currently in use, which focuses on the time- and cost-intensive testing of compounds on nerve receptors and genes. Additionally, as these peptides and proteins are naturally occurring in mammals, there is a high probability of non-toxicity; toxicity is a significant issue in the current testing process," Mr. Fater concluded.

About Vicor Technologies, Inc.

Vicor Technologies is a development-stage biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i(R)). The PD2i(R) is a deterministic, nonlinear measure that analyzes electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i(R) nonlinear algorithm. The PD2i Analyzer(TM), which has FDA 510(k) marketing clearance, measures heart rate variability and Vicor will be commencing a clinical trial to determine its efficacy to detect the presence of diabetic autonomic neuropathy (DAN).